Prefilled Syringes Market Size, Share & COVID-19 Impact Analysis, By Material (Glass and Plastic), By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System), By Product (Complete Syringe Set and Components & Accessories), By Design (Single-chamber, Double-chamber, and Multiple-chamber), By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others), and Regional Forecast, 2022-2029

The global prefilled syringes market size was USD 6.60 billion in 2021 and is projected to grow from USD 7.51 billion in 2022 to USD 15.20 billion by 2029, exhibiting a CAGR of 10.6% during the forecast period. Based on our analysis, the global market exhibited a higher growth of 17.4% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with prefilled syringes experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels.

Prefilled syringes are injectable drug delivery containers designed to administer drugs via the parenteral route. Pharmaceutical companies are considering them as one of the most effective ways of delivering a wide range of injectable drugs including biologics and biosimilar. This is the major factor contributing to the demand for prefilled syringes. They enable easy and quick delivery of drugs in case of emergencies. Innovations in prefilled syringes have led to increased patient and caregiver safety by reducing the risk of injection and dilution errors. Product development has been directed towards reducing waste and adding products to administer large volumes of medications as well. Schreiner MediPharm and SCHOTT Pharma have collaborated to develop a solution, which equips prefilled syringes with radio-frequency identification (RFID) technology. 

The rising incidence of chronic diseases, such as diabetes and other autoimmune diseases, is likely to fuel the demand of the market in the forthcoming years. For instance, according to the American Autoimmune Related Diseases Association Inc. (AARDA), about 50 million Americans suffer from autoimmune disorders currently. The growing demand for biological drugs and innovations in pre-fillable syringe technologies to fulfill the unmet needs for treating chronic disease across the globe is likely to support the global market growth. Combined with this, the increasing number of product launches by key players and high adoption of the products by healthcare professionals are factors likely to boost the prefilled syringes market during the forecast period. 

COVID-19 IMPACT

High Demand for Prefilled Products amid COVID-19 for Vaccine Production

The impact of COVID-19 on pharmaceutical packaging is expected to be high due to rapid production of vaccines for coronavirus. There is an increasing demand for such syringes over glass ampoules or any other additional needles due to reduced risk of needle-stick injuries. Therefore, to ramp up the production of the COVID-19 vaccine, the manufacturers are increasing their production capacity. For instance, the U.S. government signed a deal of USD 138 million with the syringe makers to facilitate the production of 100 million prefilled syringes for the coronavirus vaccines by the end of 2020 and more than 500 million in 2021. Additionally, in December 2020, Becton Dickinson and Co., investing about USD 1.2 billion over four years on manufacturing capabilities and technology for pre-fillable syringes and other drug delivery systems, could also be used for pandemic response.

Moreover, in 2021, the outbreak of COVID-19 has positively impacted the market. Key players have reported growth in their revenues from the sales of these syringes during the COVID-19 pandemic. For instance, the pharmaceutical systems segment of Becton Dickinson and Company (BD) medical that includes pre-fillable syringes, reported 15.2% growth during 2020-2021 while the total medical segment reported 9.2% growth between 2020-2021.

The COVID-19 outbreak has positively impacted the demand for prefilled injections. The global market is projected to grow by 17.4% in 2020 and 18.1% in 2021 due to the COVID-19 crisis, compared to 10.3% in 2019.

LATEST TRENDS

Request a Free sample to learn more about this report.

Rising Demand for Biologics & Biosimilars to Aid Market Expansion

The global life science industry is facing a drastic shift from chemical-based drugs to biologics and biosimilars. Biologics are excellent for targeted delivery and are less prone to drug-drug interaction, leading to increased inclination. The rise in biologics to treat chronic diseases has urged drug and packaging manufacturers to seek more sophisticated container closure and drug delivery systems. Therefore, this has led to a significant increase in use of these syringes for safely delivering biologics and biosimilars. For instance, according to the Central Drugs Standard Control Organization (CDSCO), a total of 98 biosimilars have been approved in India to date.

DRIVING FACTORS

Growing Innovations in Prefilled Products for Biologic Drugs to Propel Market Growth

The increasing demand for biological drugs and growing innovations in injectable delivery solutions are likely to drive the global prefilled syringes market growth during the forecast period. Biological drugs have attracted the attention of leading players as they target diseases that had no or very limited treatment options available. For instance, in April 2021, F. Hoffmann-La Roche Ltd announced the U.S. Food Drug Administration approval for its supplemental biologics application for Xolair (omalizumab) prefilled syringe intended for self-injection. Xolair is an IgE blocker indicated for asthma, nasal polyps, and chronic idiopathic urticaria. Similarly, in May 2021, Glenmark Pharmaceuticals Ltd., announced the U.S. Food Drug Administration approval for Icatibant injection, a generic version of Firazyr injection. It is available in 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe.

Additionally, the rising prevalence of cancer, autoimmune diseases, and other non-communicable diseases is likely to increase the demand for biological drugs. For instance, according to International Agency for Research on Cancer (IARC), by 2040, the global burden of cancer is expected to grow to 27.5 million new cases. Moreover, according to American Autoimmune Related Diseases Association Inc. (AARDA), about 50 million Americans suffer from autoimmune disorders currently. This number is expected to rise in future, leading to an increase in demand for biologics in the U.S.

Rising Adoption of Self-Injecting Parenteral Devices to Spur Market Growth

The use of prefilled injections as a self-injecting device is the modern way to administer parenteral drugs. These are convenient and help ease the administration process. These products help provide greater patient safety and reduce exposure to toxic products while drawing medications from the drug vials. Therefore, self-injecting devices with their pre-measured dosage reduced dosing errors and increased patient safety offer multiple advantages for the user. Hence, the above reasons contribute to increasing adoption and inclination toward this product among healthcare professionals and patients that will bode well for the growth of the global market.

RESTRAINING FACTORS

Complex Manufacturing Process and Product Recalls to Hamper Market Growth

Prefilled syringes are becoming an increasingly attractive option for complex biotechnology products. However, various product recalls due to certain impurities or leakage in the syringes restrict market growth during the forecast period. For instance, in December 2021, Novartis Pharmaceuticals U.K. recalled Lucentis 10mg/ml solution for injection in pre-filled syringes due to faulty plunger stopper that has led to an increased number of customer complaints as it was difficult to press down. Similarly, in August 2021, FDA recalled Cardinal Health’s Monoject Flush Prefilled Syringes containing 0.9% sodium chloride (12mL Syringe with 10mL Saline Fill, 3mL Saline Fill, 5mL Saline Fill). The product recall was due to possibility of the syringe’s plunger to pull air into the syringe after the healthcare provider pushed out (expelled) the air. Injecting air accidently causes embolism and may result in lethal consequences. Thus, strict regulatory requirements and manufacturing complexity and increasing recall of these products are major restraining factors for the market growth.

SEGMENTATION

By Material Analysis

Rise in Technological Innovations to Drive Plastic Segment Growth

Based on material, the global market is classified into glass and plastic.

Among them, the glass segment held the largest prefilled syringes market share in 2020. Attributed to the strong barrier property of the glass, it is a highly preferred material for manufacturing prefilled syringes. Also, it has the advantage of being highly compatible with several filling drug machines. However, certain drawbacks, such as the reaction of glass ions with the drugs and a greater chance of breakage, are expected to shift the preference of the manufacturing companies for material from glass to plastic.

The plastic segment is anticipated to be the fastest-growing segment during the forecast period due to key players involved in developing plastic syringes and growing technological innovations offering advantages over glass syringes. For instance, in September 2019, Schreiner MediPharm announced the launch of the cap-lock system for luer-lock syringes. The cap-lock feature aims to ensure the primary container’s integrity.

By Closing System Analysis

Luer Lock Form System to Exhibit Significant Growth Rate in Market

Based on closing system, the prefilled syringes market is segmented into staked needle system, luer cone system, and luer lock form system.

Among them, the staked needle system segment captured a major share in the market owing to the speedy usage of the staked needle system. However, the rising incidence of needlestick injuries is likely to reduce the growth rate of the staked needle system segment in the coming years.

Technological advancements in the luer lock form systems are making them more secure by preventing needle stick accidents. Moreover, the twisting mechanism forming a locked connection in the luer lock form system has reduced the leakage of liquid drugs, further augmenting the segment growth at a faster pace during the forecast period. For instance, in March 2019, Gerresheimer AG showcased metal-free 1 ml long luer lock Gx RTF glass syringes for bioengineered active substances at PDA annual meeting in San Diego.

By Product Analysis

Complete Syringe Set to Hold Lion’s Share in Global Market

Based on product, the market is segmented into complete syringe set and components & accessories.

Among them, the complete syringe set segment captured a major portion of the market share owing to the growing demand for these products for effective drug delivery and rising demand for self-injectable delivery systems among patients.

The components & accessories segment is expected to witness moderate growth in the market in the forthcoming years. This is attributed to the lower demand among drug manufacturing companies for independent components for prefilled injections compared to the complete set.

By Design Analysis

To know how our report can help streamline your business, Speak to Analyst

Single Chamber Segment to Capture the Largest Market Share

Based on design, the prefilled syringes market is segmented into single-chamber, double-chamber, and multiple-chamber.

Among them, the single-chamber segment captured a major share of the market and is likely to exhibit a significant CAGR during the forecast period. The growing technological innovations and shifts in preference from single-chamber syringes to a double-chamber system are likely to enhance the demand for the double-chamber system during the forecast period. Double-chamber syringes are highly efficient for storing biological components that cannot retain their stability for a longer period. Moreover, the growing penetration of lyophilized drugs worldwide is likely to surge the demand for these syringes during the forecast period.

By End-User Analysis

Pharmaceutical & Biotechnology Companies Segment to Dominate

Based on end-user, the market is categorized into pharmaceutical & biotechnology companies, contract research & manufacturing organizations, and others.

Among them, the pharmaceutical & biotechnology companies segment captured a major share in the global market. The fast-expanding pharmaceutical companies across the globe are majorly engaged in biologics, vaccines, and biosimilars. These companies have increased their demand for new drug delivery systems, such as syringes, prescribed with a unit dose of medication for better patient compliance. Moreover, a growing number of early-stage, coupled with well-funded biotech companies focused on drug discovery and development, is likely to boost the demand for syringes for effective delivery of drugs. The rise in demand for innovative injectable drug delivery systems is expected to boost the pharmaceutical & biotechnology companies’ segment growth during the forecast period.

The contract research & manufacturing organizations segment is likely to expand at a significant rate during the forecast period due to innovative technologies offering filling services.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

Geographically, the prefilled syringes market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Among them, Europe dominated the global market and generated a revenue of USD 2.66 billion in 2021. The increasing number of patients using biologics as treatment options for chronic diseases and strong adoption of advanced delivery methods for self-injection of drugs are the major factors likely to boost the demand for prefilled syringes in Europe. In addition, the presence of key players engaged in developing prefillable syringes in Europe is likely to boost the market growth. For instance, in September 2019, Nemera announced the launch of a new Safe ‘n’ Sound pre-fillable safety device for administration of Hulio biosimilar in Europe.

North America is likely to hold the second-largest market share after Europe, owing to the rise in several chronic diseases, such as diabetes and rheumatoid arthritis, which is likely to enhance the demand for prolonged drug administration at an accurate dosage. Increasing product launches and the growing presence of leading players with strong distribution networks are likely to boost the market growth in North America.

The market in Asia Pacific is likely to witness fast-paced growth during the forecast period, majorly owing to the increasing prevalence of chronic diseases, rising usage of these syringes, and rapidly growing patient population. Moreover, the rising awareness regarding innovations in these syringes and significant growth in contract manufacturing companies outsourcing packaging & filling services are likely to play a pivotal role in boosting the market growth in the region.

Latin America and the Middle East & Africa regions are likely to experience slow growth in this market due to lower awareness about innovative products and slow penetration of the market.

KEY INDUSTRY PLAYERS

Strong Product Offerings by Key Players to Propel Market Growth

Becton Dickinson and Company (BD), Gerresheimer AG, SCHOTT AG, and West Pharmaceutical Services Inc. are the leading players in this market with a strong brand presence combined with a wide range of product offerings. These players are likely to continue their dominance and generate significant revenue in the forthcoming years. Dominance is attributable to the robust research activities and continuous investments in innovative product development to launch a cost-effective and highly effective parenteral drug delivery system. Moreover, a strong focus on strategic partnerships with other key market players is likely to support expanding their footprints in the global market. For instance, in September 2019, Gerresheimer AG launched a Gx RTF ClearJect polymer needle syringe, 2.25 ml, to expand its range of prefillable polymer syringes.

LIST OF KEY COMPANIES PROFILED:

• BD (U.S.)


• Gerresheimer AG (Germany)


• SCHOTT AG (Germany)


• West Pharmaceutical Services Inc. (U.S.)


• Helvoet Rubber & Plastic Technologies BV (Netherlands)


• Nipro PharmaPackaging International (Belgium)


• AptarGroup, Inc. (U.S.)


• Terumo Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS:

• April 2021: Nipro Pharma Packaging International expanded its product portfolio by announcing that the Nipro D2F pre- fillable syringes are compatible with Schreiner MediPharm Needle- Trap (safety system).


• October 2021: Becton, Dickinson and Company partnered with Aptar Pharma and launched BD SCF PremiumCoat Plunger Stopperade to support biologics injection with pre-filled syringe.

REPORT COVERAGE

An Infographic Representation of Prefilled Syringes Market

View Full Infographic

To get information on various segments, share your queries with us

The prefilled syringes market report provides detailed information regarding various insights into the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of the market trends and estimations to illustrate the forthcoming investment opportunities. The market is quantitatively analyzed from 2018 to 2029 to provide the financial competency of the market. The information gathered in the report has been taken from several primary and secondary sources.

Report Scope & Segmentation